| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| Referral date | 01 April 2009 |
| Topic area |
|
| Description |
Cancer reform strategy Batch 6 |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Laura Gibson |
| Executive Lead: | Gillian Leng |
| Project manager: | Jeremy Powell |
| Technical Lead: | Scott Goulden |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 4 January 2010 | The manufacturer of denosumab has indicated that they will not make a submission for this appraisal. We have therefore suspended the appraisal. |
| 2 August 2010 | Denosumab has not received a separate marketing authorisation for this indication. The Department of Health have therefore removed this appraisal from NICE’s work programme. |
For further information on our processes and methods, please see our CHTE processes and methods manual